Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acids and salts thereof
Reexamination Certificate
2011-08-02
2011-08-02
Kosar, Andrew D (Department: 1622)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acids and salts thereof
C564S305000
Reexamination Certificate
active
07989656
ABSTRACT:
The present invention relates to biaryl carboxylic acid compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing these compounds and methods of treating diseases which express the Mcl-1 protein.
REFERENCES:
patent: 2002/0055631 (2002-05-01), Augeri et al.
patent: 2002/0086887 (2002-07-01), Augeri et al.
patent: 2003/0073862 (2003-04-01), Gustavsson et al.
patent: WO0224636 (2002-03-01), None
patent: WO2006062093 (2006-06-01), None
Backus et al., “Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer,” Annals of Oncology, vol. 12, pp. 779-785, 2001.
Baekelandt et al., “Expression of Apoptosis-Related Proteins Is an Independent Determinant of Patient Prognosis in Advanced Ovarian Cancer,” Journal of Clinical Oncology, vol. 18 No. 22, pp. 3775-3781, 2000.
Chung et al., “Expression of apoptotic regulators and their significance in cervical cancer,” Cancer Letters, vol. 180, pp. 63-68, 2002.
Deininger et al., “Antiapoptotic Bcl-2 Family Protein Expression Increases with Progression of Oligodendroglioma,” Cancer, vol. 86 No. 9, pp. 1832-1839, 1999.
Eerola et al., “Accelerated Apoptosis and Low Bcl-2 Expression Associated with Neuroendocrine Differentiation Predict Shortened Survival in Operated Large Cell Carcinoma of the Lung,” Pathology Oncology Research, vol. 5 No. 3, pp. 179-186, 1999.
Fong et al., “Mcl-1 Expression in Gestational Trophoblastic Disease Correlates with Clinical Outcome,” Cancer, vol. 103 No. 2, pp. 268-276, 2005.
Gomez-Bougie et al., “The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells,” European Journal of Immunology, vol. 34, pp. 3156-3164, 2004.
International Search Report for application No. PCT/US2006/026424, Mailed on Dec. 29, 2006, 3 pages.
Kaufmann et al., “Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse,” Blood, vol. 91 No. 3, pp. 991-1000, 1998.
Kuramoto et al., “High Expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma,” British Journal of Haematology, vol. 116, pp. 158-161, 2002.
Maeta et al., “Expression of Mcl-1 and p53 proteins predicts the survival of patients with T3 gastric carcinoma,” Gastric Cancer, vol. 7, pp. 78-84, 2004.
Moshynska et al., “Prognostic Significance of a Short Sequence Insertion in the Mcl-1 Promoter in Chronic Lymphocytic Leukemia,” Journal of the National Cancer Institute, vol. 96 No. 9, pp. 673-682, 2004.
Packham et al., “Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia,” Immunology, vol. 114, pp. 441-449, 2005.
Petros Am et al., “Discovery of a potent inhibitor of the antlapoptotic protein Bcl-Xl from NMR and parallel synthesis,” Journal of Medicinal Chemistry, 2006, 49, pp. 656-663.
Rassidakis et al., “BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation,” Journal of Pathology, vol. 200, pp. 240-248, 2003.
Shi et al., “Acquired Resistance of Pancreatic Cancer Cells towards 5-Fluorouracil and Gemcitabine Is Associated with Altered Expression of Apoptosis-Regulating Genes,” Oncology, vol. 62, pp. 354-362, 2002.
Soini et al., “Apoptosis and Expression of Apoptosis Regulating Proteins bc1-2, mcl-1, bcl-X and bax in Malignant Mesothelioma,” Clinical Cancer Research, vol. 5, pp. 3508-3515,1999.
Strik et al., “BCL-2 Family protein expression in initial and recurrent glioblastomars modulation by radiochemotherapy,” J Neurol Neurosurg Psychiatry, vol. 67, pp. 763-768, 1999.
Augeri David
Dickman Daniel A.
Ding Hong
Elmore Steven W.
Shen Wang
Abbott Laboratories
Kosar Andrew D
Manzari Oona
Rodriguez-Garcia Valerie
LandOfFree
Biaryl carboxylic acid apoptosis promoters does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biaryl carboxylic acid apoptosis promoters, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biaryl carboxylic acid apoptosis promoters will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2668568